Hester Biosciences

These 3 pharma stocks have surged over 50% in April; check full list here

A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.

Hester Biosciences Q3 results: Net profit jumps 3-fold to Rs 11.41 cr

Hester Biosciences Ltd on Thursday reported a nearly three-fold jump in profit for the December quarter of 2024-25, mainly driven by foreign exchange gains. The company's profit after tax stood at Rs 11.41 crore in the October-December quarter of 2024-25 compared to Rs 4.02 crore in the year-ago period, an exchange filing said. Revenue from operations dropped by 6 per cent to Rs 63.22 crore for the third quarter of 2024-25 compared to Rs 66.98 crore in the year-ago period. The company recorded an unrealised foreign exchange gain of Rs 7.83 crore due to currency fluctuations. Revenue from animal healthcare division dropped 24 per cent while that from poultry segment rose by 12 per cent and from pet care more than doubled during the quarter. Rajiv Gandhi, CEO and MD of Hester Biosciences said, Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is

Poultry vaccine maker Hester Bio enters pet care, no fresh investment seen

Is now looking to add dermatology, nutrition, grooming, anti-infective and specialty products in this segment

Hester Bio surges 22% in 2 days on tech transfer for manufacturing Covaxin

The technology transfer from Bharat Biotech will enable Hester to provide the drug substance from August 2021 to BB for its vaccine production

Hester Biosciences zooms 33% in 2 days as firm in talks to produce Covaxin

The company said it has tied up with the Gujarat government to explore the production of Covid-19 vaccine through technology transfer from Bharat Biotech

Hester in talks with Bharat Biotech to produce Covaxin via tech transfer

Hester Biosciences on Sunday said it has tied up with the Gujarat government to explore the production of the Covid-19 vaccine through technology transfer from Bharat Biotech

Indigenous players on a slow and steady coronavirus vaccine race

Smaller players are bullish on playing crucial role in nation's vaccine infrastructure

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Hester Bio Q3 PBT dips 10% at Rs 14.95 crore; total revenue grows 10%

The company's consolidated total revenue grew by 10.87 per cent to Rs 50.99 in Q3 of FY'20 as compared to Rs 45.99 crore in Q3 of FY'19

Hester Biosciences dips post September quarter results

The stock dipped 7% to Rs 716, falling 9% from intra-day high on BSE.

Hester Biosciences gains on fund raising plan via QIP

The stock rallied 9% to Rs 777 after the company said that the board will meet on June 29 to consider to raise funds.

Hester Biosciences surges on healthy Q4 results

The stock has surged 19% to Rs 630 after posting 56% YoY growth in net profit at Rs 55 crore in Q4FY16

Hester Bio Q4 standalone net rises 57% to Rs 5.5 cr

Net sales rise to Rs 28.18 cr for quarter under review as against Rs 23.36 cr in the year-ago period